Find Clinical Trials

Inclusion Criteria: * All children more than 1 month and less than 18 years cases with bronchial asthma and acute bronchiolitis Exclusion Criteria: * All children less than 1 month and more than 18 years congenital heart disease

Inclusion Criteria: 1. Pathologically confirmed AJCC 7th/8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast. 2. Measurable disease in the breast, suitable to receive radiotherapy. 3. Receiving or planned to receive systemic therapy. a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4/6 inhibitors, T-DXd 4. Patients are allowed to have SABR for oligometastatic disease as clinically indicated 5. Age 18 or older 6. ECOG Performance Status 0-2 7. Life expectancy greater than 6 months 8. Able and willing to provide informed consent 9. Able to complete patient reported outcome questionnaires Exclusion Criteria: 1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy 2. Previous history of locoregional radiotherapy to the ipsilateral breast

Inclusion Criteria: 1. Male or female, Age 18 - 65, inclusive 2. Currently meets DSM-5 diagnosis of MDD without psychotic features, Current major depressive episode of at least 4 weeks in duration at screening 3. Identified as MDD by Mini-international Neuropsychiatric interview (M.I.N.I.) 4. MADRS score ≥25 and CGI-S ≥4 at screening and baseline 5. The results of physical examination and laboratory tests during the screening period meet the test requirements 6. Body Mass Index between 18 and 40 kg/m2, inclusive 7. For male subjects, use of an adequate method of birth control by the subject and by female sexual partners Exclusion Criteria: * 1\. The researchers determined that it was refractory depression \[defined as in a current depressive episode or a previous depressive episode, After 2 or more antidepressants, a sufficient amount (in the maximum recommendation of the manual), a course of foot therapy (at least even Continued medication for 4-6 weeks) ineffective after treatment\] 2. The MADRS score improved by ≥ 25% at baseline compared with the screening period. 3\. Hospitalization in a psychiatric hospital during a current depressive episode 4. There is a clinically significant risk of suicide or self-harm and harm to others 5. Screening patients tested positive for substance abuse 6. In the investigator's judgment, there are any clinically significant oncology, hematology, or internal diseases that are not suitable for entry into the study Secretory/metabolic, cardiovascular, respiratory, kidney, liver, gastrointestinal, infectious or nervous system fever Or suffer from an unstable or progressive chronic disease 7. hypertension 8. Hypothyroidism or hyperthyroidism, except for the following cases: receiving stable medication with no change in dose for at least 1 month before screening (serum TSH must be \> 0.75×LLN（ Lower Limit of Normal ） and \< 1.25×ULN（Upper Limit of Normal ）) 9 Bupropion, dextromethorphan, opioids (such as codeine), or any of the study drugs Allergic to other ingredients 10. Presence of a history of intolerance to bupropion or dextromethorphan 11. People living with HIV, or testing positive for HIV during screening 12. Screening period hepatitis virology test positive 13. Liver enzyme test results during the screening period (total bilirubin, aspartate aminotransferase and/or alanine aminotransferase) \> 2.0 × ULN 14. According to the investigator's judgment, other conditions are not suitable for participating in this clinical study

Inclusion Criteria: * Patients must have histologically confirmed malignancy that is metastatic or locally recurrent unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Patients must have histologically or cytologically confirmed non-IBC triple negative breast cancers, defined here as ER\<1%, PR\<1% and HER2 negative per ASCO CAP 2018 guideline. OR * Inflammatory breast cancer (IBC) confirmed according to international consensus criteria that is ER\<20% and PR\<20%. * At least 1 week since prior chemotherapy or radiation therapy * Age .18 years. * Has at least one measurable lesion per RECIST 1.1 * ECOG performance status . 2 (Karnofsky . 60%,). * Patients must have adequate organ and marrow function as defined below: * absolute neutrophil count . 1,000/mcL * hemoglobin \>9 mg/dL * platelets . 100,000/mcL * total bilirubin . institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) . 3 \~ institutional ULN; . 5 \~ institutional ULN if confirmed liver metastasis and elevation is deemed to be directly due to metastasis. * Creatinine clearance .30 mL/min (measured by the Cockcroft-Gault equation\*). * Ability to understand and the willingness to sign a written informed consent * . Cognitively impaired subjects will not be enrolled in this study. * Negative serum pregnancy test within 72 hours of receiving the first dose of the study medication for women of childbearing potential as per institutional guidelines. * Subjects of childbearing potential must be willing to use highly effective birth control methods or be surgically sterile or abstain from heterosexual activity for the course of the study. Women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). * History of bilateral tubal ligation or another surgical sterilization procedure. * Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of all study drug administration. Exclusion Criteria: * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) except for alopecia. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to \> Grade 2 for at least 3 months prior to \[enrollment/Cycle 1 Day 1\] and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, including: Chemotherapyinduced neuropathy, Fatigue, Residual toxicities from prior IO treatment: Grade 1 or Grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism, Type I diabetes, Hyperglycemia, Adrenal insufficiency, Adrenalitis and Skin hypopigmentation (vitiligo) * Patients with a history of interstitial lung disease (past or current) or active, non-infectious pneumonitis. * Patients with active autoimmune disease requiring systemic immunosuppression with corticosteroids (\> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, axatilimab, retifanlimab used in study. * Patients with uncontrolled intercurrent illness. Medical history or complication considered inappropriate for participation in the study, or a serious physical or psychiatric disease, the risk of which may be increased by participation in the study in the investigator's opinion. * Patients with active infections requiring systemic antibiotics or antifungal or antiviral treatment within 14 days of C1D1 study treatment. * Patients with known active Hepatitis B or Hepatitis C infection. Testing is required to establish eligibility. Active Hepatitis B infection is defined as a positive Hepatitis B surface antigen and positive Hepatitis B core antibody test. Active Hepatitis C infection is defined assay. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Patients with known HIV infection, defined as positive for HIV1/2 antibodies. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study due to potential for teratogenic or abortifacient effects. * Patients who are cancer survivors other than cured non-melanomatous skin cancer or cured cervical carcinoma in situ and thyroid cancer will be excluded from the study as other cancers can recur. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Patients with active brain metastasis if treatment is warranted. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)- directed therapy shows no evidence of progression. * Patients with known leptomeningeal disease, defined as unequivocal imaging or cytologyproven disease. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better, and EF greater than 45% despite best supportive cae. * Patients with a history or presence of screening ECG test that is clinically significantly abnormal in the investigator's opinion. Patients with a prolonged Qtc interval \> 480 milliseconds (corrected by Fridericia or Bazett formula are excluded, but medically controlled arrhythmias are allowed. * Patients with a history of significant cardiac event within 6 months of C1D1. Significant cardiac events include baseline NYHA class III/IV cardiac disease, acute myocardial infarction, severe/unstable angina, cardiomyopathy, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, critical conduction delay, transient ischemic attack or pulmonary embolism. * Patients who are receiving any other investigational agents.

Inclusion Criteria: * Provision of signed and dated informed consent form * Age 18 years or older * Presence of one or more of the following conditions: type 2 diabetes or hypertension. (Type 2 diabetes and hypertension will be defined by the combination of a self-reported physician diagnosis of one of the conditions and at least one pharmacy prescription for one of the conditions.) * Able to converse, and complete the research surveys in English or Spanish, based on self-report. * Positive screening for food or nutrition insecurity by: 1. Hunger Vital Sign™ screening and, 2. Nutrition Security Screener Exclusion Criteria: * Unable to provide informed consent. * Unable to read and write. * Self-reported serious medical conditions that may be expected to shorten life expectancy to less than one year * A condition that limits participant's ability to grocery shop or choose food for themselves * Plans to move to a new home in the next 6 months that would require use of a different pharmacy * Currently pregnant or pregnancy planned within the next 6 months * Currently using or planning to start an insulin pump or other automated insulin delivery device within the next 6 months * Currently on a GLP-1 agonist or planning to start a GLP-1 agonist within the next 6 months * Currently receiving or planning to receive within the next 6 months another Food is Medicine program, like PRx, Grocery Rx, or Medically Tailored Meals

Main Inclusion Criteria: * Male or female participants with body mass index (BMI) ≥27.0 kg/m2. * Diagnosed with type 2 diabetes ≥180 days prior to the day of screening. * Treated with metformin with or without sodium-glucose cotransporter 2 inhibitors. Treatment should be stable (same drug\[s\], dose, and dosing frequency) for at least 90 days prior to screening. Main Exclusion Criteria: * Severe hypoglycemia within 6 months prior to screening or history of hypoglycemia unawareness. * Receipt of any other glucose-lowering drug than those listed in the inclusion criterion within 90 days prior to screening. * A self-reported change in body weight \>5% within 90 days prior to screening, irrespective of medical records. * Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 90 days prior to screening. * Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g., sleeve, banding, or similar) that have been removed more than 6 months prior to screening, are allowed. * Obesity due to endocrine disorders or genetic syndromes.

Inclusion Criteria: The inclusion criteria for adolescents are as follows: * Unmarried, 13-15 years old, school-going, healthy adolescents enrolled in an Indonesian public junior high school * Able to read, understand, and converse in Bahasa Indonesia. The inclusion criteria for parents are as follows: * The biological father, mother, or an adult who fulfils a parental or guardian role for the participating adolescent * Able to understand and communicate in Bahasa Indonesia. Exclusion Criteria: * Adolescents who are working, clinically diagnosed with severe mental disorders, such as schizophrenia or psychosis, at high risk for mental health disorders (e.g., teenage pregnancy), or are cognitively impaired will be excluded. * Parents with severe mental disorders or cognitive impairment that may hinder participation will be excluded.

Inclusion Criteria: • Speak English, Spanish, Arabic, Chinese, French, Hindi, Finnish, Albanian, Russian or Tagalog Exclusion Criteria: * significant eye pain * sudden decrease in vision within one week * binocular diplopia * cognitive impairment * pregnancy * previously declined participation

Inclusion Criteria: * Any adult being treated for HIV PrEP at one of the centres taking part in the study * Have French social security coverage Exclusion Criteria: * Follow-up to HIV * First consultation for PrEP * Limited understanding of French to answer questionnaires

Inclusion Criteria: * Age between 18 and 65 years; * Current diagnosis of Major Depressive Disorder (MDD), confirmed by MINI; HDRS-17 score between 8 and 23 at baseline; * Stable antidepressant regimen for at least 6 weeks prior to enrollment; * Able and willing to provide informed consent. Exclusion Criteria: * Diagnosis of other psychiatric disorders (e.g., bipolar disorder, psychotic disorders, OCD, ADHD, personality disorders, dementia); * Substance or alcohol use disorders; * Severe suicidal ideation or psychotic symptoms; * HDRS-17 score \>28; * Neurological or severe medical conditions; * History of epilepsy, migraine, or photosensitivity; * Retinal disease or cataracts; * Regular use of anti-inflammatory medications or clopidogrel; * Any worsening of symptoms during the trial (e.g., psychosis, HDRS \>28, or suicidal ideation); * Participation in another clinical trial within the last 30 days.

Inclusion Criteria: (1) Age: 18 to 80 years old (inclusive), without restrictions on gender or ethnicity. (2) Disease Diagnosis: 1. COPD patients must meet the GOLD diagnostic criteria, with post-bronchodilator FEV1/FVC \< 70% and FEV1 \< 80% of the predicted value. 2. Asthma patients must meet clinical diagnostic criteria, including recurrent wheezing, shortness of breath symptoms, frequently occurring at night; during attacks, wheezing sounds can be heard in both lungs; effective treatment with bronchodilators or corticosteroids, or symptoms can be relieved spontaneously, and at least one of the following tests must be positive: positive bronchial provocation test; positive bronchodilator test with FEV1 increase ≥12%, and FEV1 increase absolute value ≥200ml; daily peak expiratory flow (PEF) variability ≥10% within one week. 3. Bronchiectasis patients must meet the diagnostic criteria based on CT imaging, including: bronchial diameter/accompanying pulmonary artery diameter ratio \>1; high-resolution CT (HRCT) showing dilated cystic, columnar, or cystic bronchial shadows. (3) Disease Status: 1. Patients with chronic airway inflammation must be in a stable phase, defined as no acute exacerbations, hospitalizations, or use of other treatments for at least 4 weeks. 2. COPD patients with acute exacerbations must meet the definition of acute exacerbation: at least two major symptoms (dyspnea, increased sputum, and purulent sputum) worsen, or at least one major symptom and one minor symptom (wheezing, sore throat, cough without other causes, and fever) worsen. 3. Asthma patients in the acute attack phase must meet the definition of acute attack: sudden worsening of symptoms (including wheezing, shortness of breath, chest tightness, cough, etc.), decreased lung function, poor response to routine treatment, other clinically diagnosed acute attacks. 4. Bronchiectasis patients with acute exacerbations must meet the definition of acute exacerbation: increased cough, increased sputum or sputum viscosity, purulent sputum, dyspnea or decreased exercise tolerance, fatigue or discomfort, hemoptysis, at least three of the above six symptoms occur newly or significantly worsen, lasting ≥48 hours. (4) Treatment Status: 1. In the chronic airway inflammation patient ICS treatment study, patients must require ICS treatment under routine care, i.e., have been recommended to use ICS and are currently using ICS treatment. 2. In other studies, patients must maintain unchanged long-term medication during the follow-up period, but may be appropriately adjusted according to the attending physician's clinical decision. (5) Others: 1. All participants must voluntarily participate in the study and sign the informed consent form. 2. Patients must be able to communicate in language or writing, understand and sign the content of the informed consent form, and be able to complete the required pulmonary function and other auxiliary examinations for the trial. Exclusion Criteria: (1) Recent Medication Use: 1. In the chronic airway inflammation patient ICS study, exclude patients who have used corticosteroid-related treatment within the last 3 months, exclude patients who have received antibiotic treatment within the last 3 months. 2. In other studies, exclude patients who have used antibiotics, immunosuppressants, cytotoxic agents, or hormones systemically within the last 4 weeks. (2) Other Significant Diseases: 1. Clinically significant pulmonary diseases other than the study disease, such as active tuberculosis, pulmonary embolism, pneumothorax, pneumothorax, pulmonary hypertension, interstitial lung disease, lung cancer, pulmonary fibrosis, tuberculosis, etc. 2. Severe other systemic diseases, such as myocardial infarction, severe arrhythmia, liver dysfunction, renal insufficiency, rheumatic immune system diseases, hematological diseases, active malignant tumors, etc. (3) Disease Status: \[1\] Patients who have experienced any degree of acute exacerbation within the last 4 weeks before screening for the stable phase study. (4) Special Populations: 1. Female patients who are pregnant or breastfeeding. 2. Patients with poor compliance. 3. Patients who cannot complete sample collection due to physical or psychological factors, especially those who need to collect multiple samples. 4. Patients who are participating in other clinical trials. (5) Related Contraindications: \[1\] Patients with contraindications to pulmonary function tests and chest CT, such as chest metal, history of myocardial infarction, stroke, aortic aneurysm, or ocular surgery or retinal detachment within the last 3 months.

Inclusion Criteria: 1. Adult and adolescent patients (age ≥12 years) at the Index Date (i.e., first administration of tezepelumab); 2. Patients with severe uncontrolled asthma (diagnosed according to clinician's judgment as per ERS-ATS or GINA guidelines) requiring a stable treatment of high doses of ICS and a long acting β2 agonist ± additional asthma controller; 3. Patients who received at least one injection of tezepelumab from February 2024 to March 2025 , according to Italian reimbursement indications; 4. Patients who signed the ICF and privacy form. 5. Patients with continuous enrolment in the data source for at least 12-months before the index date. 6. Patients with at least three months of continuous enrolment in the data source after the index date. Exclusion Criteria: 1. Patients with hypersensitivity to the active ingredient or any of the excipients of Tezspire; 2. Patients who received any biologic drug for the treatment of asthma in a clinical trial at any time during the 12-months prior to the index date. 3. Patients who, during the observation period, participated in studies imposing a specific patient's management strategy, which does not correspond to the site's normal clinical practice.

Inclusion Criteria: * Subjects pathologically confirmed with ER-positive, HER2-negative breast cancer; * Subjects with locally advanced (unresectable) or metastatic breast cancer who have disease recurrence during or after adjuvant endocrine therapy, or whose disease has progressed after 1-2 lines of systemic endocrine therapy; * Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria; in the absence of measurable lesions, subjects with evaluable bone lesions \[osteolytic or mixed (osteolytic + osteogenic) bone lesions\] are also acceptable. Lesions that have been previously treated with radiotherapy or other local therapy can be regarded as measurable lesions only if there is disease progression as confirmed by imaging examination; * Expected survival time ≥ 12 weeks; Exclusion Criteria: * Subjects with unstable or symptomatic or progressive central nervous system (CNS) metastases. Subjects with a history of brain metastases who are clinically stable and have no CNS disease progression confirmed by brain MRI or CT (if MRI is not appropriate) can be enrolled (MRI or CT examination must be conducted at least 4 weeks after the last brain radiotherapy); * Subjects with locally advanced or metastatic breast cancer who have previously received more than 2 prior systemic chemotherapy; * Subjects are unsuitable for endocrine therapy judged by the investigator, including uncontrolled pleural effusion, ascites or pericardial effusion; * Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases; * Prior treatment with a selective estrogen receptor degrader (SERD)/selective estrogen receptor covalent antagonist (SERCA), such as fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn -c5, LX-039, HS234, etc.; * Pregnant or lactating females;

Inclusion Criteria: * Have a diagnosis of mild-to-moderate asthma (Global Initiative for Asthma 2023 criteria) ≥ 1 year prior to Screening * Maintain FeNO-high (≥ 25 parts per billion \[ppb\]) or FeNO-low (\< 25 ppb) status from Screening to Day 1 prior to Randomization * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 60% of predicted normal value at Screening * Asthma Control Test (ACT) score \> 19 at Screening * Maintained control on as-needed short-acting beta-agonist (SABA) +/- stable dose inhaled corticosteroids (ICS) or stable dose of ICS/ long-acting beta-agonist (LABA); +/- stable dose leukotriene receptor antagonist (LTRA). ICS dose should be stable for ≥ 12 weeks prior to Day 1, LTRA dose should be stable for ≥ 8 weeks prior to Day 1 * Women of childbearing potential and male participants to use a highly effective form of contraception Exclusion Criteria: * Any asthma exacerbation requiring systemic corticosteroids within 12 weeks of Screening and/or any asthma exacerbation that resulted in overnight hospitalization within 6 months prior to Screening * Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia * History of biologics use for treatment or control of asthma * Current smokers or participants with a smoking history of ≥ 10 pack years * Known history of illicit drug abuse, harmful alcohol use Note: Other protocol defined criteria may apply.

Inclusion Criteria: * 18 years of age and above; * Women of any menstrual status; * Histologically confirmed recurrent or metastatic breast cancer, including patients initially diagnosed as stage IV or locally advanced inoperable; * Patients with histological pathology that is clearly HR-positive/HER2-negative breast cancer, or if there is metastatic pathology, the histological pathology of the metastatic foci shall prevail. (Those with ER intensity \>1% cellular nuclear staining) * Patients have at least 3 more fully documented medical records at the enrolled centre, including at least 1 inpatient record. Exclusion Criteria: * CDK4/6 inhibitors as neoadjuvant or adjuvant therapy; * Significantly missing diagnostic and treatment data from patients' medical records; * Participation in other clinical trials before and during the data collection period.

Inclusion Criteria: 1. Participants voluntarily enrolled in the study, signed the informed consent form, and demonstrated good compliance. 2. Age ≥ 18 years at the time of informed consent signing. 3. Patients with locally advanced or recurrent/metastatic breast cancer receiving TROP2-ADC treatment for the first time. 4. ECOG PS: 0-2 points; 5. The expected survival time was more than 3 months; 6. Adequate organ and bone marrow function, with no transfusions or treatments with recombinant human thrombopoietin or colony-stimulating factors within 1 week before the first dose, is defined as follows: 1. Blood routine: Neutrophil count (NEUT#) ≥ 1.5×109/L; Platelet (PLT) ≥ 75×109/L; Hemoglobin ≥ 90g/L 2. Liver function: AST and ALT ≤ 3 × ULN; for patients with liver metastasis, AST and ALT ≤ 5 × ULN. 3. Renal function: Creatinine ≤ 1.5 × ULN or Ccr ≥ 60 ml/min (Cockcroft-Gault formula provided). 4. Cardiac function: LVEF ≥ 50% by ECHO or MUGA scan. 7. Patients with a negative pregnancy test and reproductive potential must agree to use effective non-hormonal contraception during treatment and for at least 3 months after the last dose of the investigational drug. 8. Voluntary participants who sign informed consent, demonstrate good compliance, and agree to follow-up. Exclusion Criteria: 1. Prior TROP2-targeted treatment was administered. 2. Patients with active oral mucositis or oral ulcers were excluded. 3. Patients with serious concomitant diseases, as judged by researchers, that threaten safety or impede study completion, including uncontrolled hypertension, severe diabetes, and active infections, were excluded. 4. Other conditions where the investigator determines the patient is unsuitable for study participation.

Inclusion Criteria: * Age \> 18 * Type 2 diabetes for at least 12 months * On insulin pump for at least 6 months, without/with adjuvant treatment exclusively with GLP1-Ra, iSGLT2, metformin for at least 3 months * Autonomy in the management of the pump and the glucose sensor * HbA1c ≥ 7.5% and \< 12 * Participant's agreement to wear and use the Ypsomed with the CamAPS HX algorithm and Free Style Libre 3 sensor, and to honor the study visit schedule * For women of childbearing age, effective contraception is required (estrogen-progestin pill, IUD, implant). Exclusion Criteria: * Type 1 diabetes or monogenic diabetes * Use of U500 or U200 insulin concentrate in the pump in the last 3 months * Allergy to insulin or to the adhesives used * Severe insulin resistance defined by a daily insulin requirement of more than 1.5 U/kg * History of severe hypoglycemia \> 1 time in the last 6 months. * Current or planned use of steroids (oral, injectable) or any treatment likely to have an impact on blood glucose levels within the last 30 days. * Current or planned pregnancy, breastfeeding * Severe renal failure defined as GFR \< 30 ml/mn * Proliferative retinopathy or severe maculopathy with risk of worsening during the study * Vision or hearing problems that could compromise safe use of the device * Acute vascular event within the last 3 months * No autonomy for pump treatment * Alcohol or substance abuse * Legal protection (guardianship, curatorship) * Any somatic or psychological condition compromising participation in the study * Participation in another clinical trial

Inclusion Criteria: 1. Age \>18 years 2. Patients undergoing mastectomy with immediate reconstruction using ICG-NIR 3. Patients are mentally competent 4. Written informed consent Exclusion Criteria: 1. Patients with known allergy to ICG or iodinated contrast media 2. Pregnant or lactating women 3. Patients with dialysis-dependent renal failure and renal transplantation

Inclusion Criteria: 1. Age ≥18 years old and ≤75 years old, gender is not limited; 2. Body mass index (BMI) ≥18 and ≤30 kg/m2 during screening period; 3. Medical history and objective evidence consistent with current guidelines supporting an asthma diagnosis within the 12 months prior to randomization; 4. Did not receive inhaled corticosteroids (ICS) and/or combined with other asthma control medications within 2 weeks prior to randomization; 5. FEV1 during the screening period and before bronchodilator inhalation at baseline accounted for ≥40% and \< 80% of the estimated value; 6. Screening and baseline visit, Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5; 7. FeNO values at screening period and baseline ≥25 ppb; 8. Patients with asthma who were treated for the first time or who had previously taken irregular medication were selected; Among them, the definition of irregular past use was: patients did not regularly use asthma control drugs within the first 3 months of enrollment, and the average weekly use compliance was \< 50%. 9. A fertile female subject or a male subject whose partner is a fertile female must agree not to have a family plan and to voluntarily use highly effective contraception (including the partner) from the time of signing the informed consent until 1 month after the last study drug administration, and refrain from sperm/egg donation; 10. Voluntarily sign informed consent to participate in this study. 11. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card. 12. The researchers determined that there were other circumstances that were not suitable for participation in this study. Exclusion Criteria: 1. Combined diseases or conditions * Clinically significant pulmonary diseases, including but not limited to active pulmonary tuberculosis, bronchiectasis, atelectasis, idiopathic pulmonary fibrosis, bronchopulmonary aspergillosis, and chronic obstructive pulmonary disease (COPD); * Malignant tumors diagnosed within 5 years prior to randomization (except those with a low risk of metastasis and death, such as well-treated basal cell carcinoma of the skin or carcinoma in situ of the cervix); * Combined with poorly controlled hypertension (systolic blood pressure ≥180mmHg, and/or diastolic blood pressure ≥110mmHg during the screening period) or uncontrolled severe cardiovascular and cerebrovascular diseases; ④ Known immunodeficiency; * A history of infection requiring clinical intervention within 4 weeks prior to randomization, including but not limited to respiratory infection; ⑥ Known presence of parasitic infection within 6 months prior to randomization; ⑦ Blood donation or significant blood loss (≥400ml), or transfusion of blood products or immunoglobulin within 4 weeks prior to randomization; ⑧ A history of life-threatening acute asthma attacks (including admission to the intensive care unit and/or the need for invasive ventilator support \[intubation/tracheotomy\]); ⑨ History of acute asthma attack in the 4 weeks prior to randomization. 2. Combination of medication or treatment * Receiving non-selective beta-blockers (e.g., propranolol) within 1 week prior to screening; * Live attenuated vaccine or recombinant vaccine with viral vector were received within 4 weeks before randomization; * Receiving allergen immunotherapy 8 weeks before randomization; * Within 12 weeks before randomization or within 5 half-lives of the drug (refer to the drug instructions, whichever is older; For those with unknown half-lives, the first 12 weeks of randomization will be the use of systemic immunosuppressants (except for systemic glucocorticoids for asthma treatment, and systemic glucocorticoids for other conditions \<3 days) or immunomodulators, or biologics or Th2 cytokine inhibitors, Including but not limited to methotrexate, cyclosporine, interferon-alpha, anti-IL-5 monoclonal antibody,anti-TSLP monoclonal antibody, anti-IGE monoclonal antibody, mesulast, etc. * Receiving a single dose of long-acting β2 agonist within 4 weeks prior to screening; ⑥4 weeks before randomization, inhaled corticosteroids (\>500 micrograms of beclomethasone dipropionate per day \[BDP\] or equivalent dose); ⑦4 weeks before randomization, systemic glucocorticoid therapy; * Received bronchial thermoplasty or bronchial cryoablation within 1 year before randomization; ⑨There is a surgical plan during the study, or other treatment that the investigator believes may affect the evaluation of the subject; 3. Laboratory examination ①Significant abnormalities during screening or baseline laboratory tests: 1. White blood cell (WBC) \< 3.0×109/L; 2. Blood eosinophils \>1500cells/μL (1.5×109/L) 3. Hemoglobin (Hb) ≤90 g/L; 4. Alanine aminotransferase (ALT) \> 3×ULN (upper limit of normal); 5. Aspartate aminotransferase (AST) \> 3×ULN; 6. Total bilirubin (TBIL) \> 1.5×ULN; 7. Prothrombin time (PT) \> ULN+3s; 8. Creatinine (Cr) \> 1.5×ULN; 9. Co-active hepatitis B (peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥1×103 IU\[or copy\] / mL), or hepatitis C antibody positive, or human immunodeficiency virus (HIV) positive, or treponema pallidum antibody positive. * Prolonged ECG QTc interval (\>450ms) or other clinically significant abnormal results that may pose significant safety risks to subjects during the screening period; 4. General situation * Smoking or smoking cessation less than 6 months during the screening period, or previous smoking ≥10 pack years (pack years = number of years of smoking × number of packs per day); ②A history of drug use, alcohol abuse (average weekly consumption of ≥14 units of alcohol: 1 unit = 285 mL for beer, 25 mL for spirits, or 100 ml for wine) or drug abuse in the year prior to screening; * Have participated in other clinical studies and used investigational drugs containing active ingredients within 30 days prior to screening, or have been within 5 half-lives of investigational drugs at the time of screening (whichever is older); * Subjects who are pregnant (screening or baseline blood pregnancy test positive) or who plan to become pregnant while breastfeeding or during the study; ⑥Other reasons deemed unsuitable for study participation by the researcher. * Excessive alcohol consumption and drug abuse were prohibited throughout the study period (the definition of excessive alcohol consumption is the same as exclusion criterion IV.2). * Smoking (including e-cigarettes) was prohibited throughout the study period.

Inclusion Criteria: 1. They met criteria for a DSM-5 diagnosis of a Major Depressive Episode (MDE) during the index episode of depression for which they have received an acute rTMS treatment course. 2. Meet criteria for either response or remission from their initial depressive illness. The MINI assessment timeline will be adjusted to allow scoring of illness symptoms prior to rTMS response. Response to acute course of treatment is defined as either a MADRS score of \<10, or a MADRS score of 10-19, plus evidence of having met response criteria on either the MADRS or another structured depression rating scale. The response is defined as a \>50% reduction in the total score from the start to the end of treatment. 3. Their initial rTMS treatment course must have consisted of at least 15 rTMS treatment sessions. 4. People between the ages of 18 and 80 at the time of screening. A written statement from the referring physician will be required to confirm that the participant demonstrates the capacity to consent. 5. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during TMS-EEG assessments and iTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. 6. In good general health, as evidenced by medical history. 7. Agreement to adhere to Lifestyle Considerations throughout study duration. 8. If a person of child-bearing potential is: must take a pregnancy test at the screening visit, with results confirmed as negative by study staff Exclusion Criteria: * 1\. Pregnancy 2. History of or current psychotic disorder or depression with psychotic features 3. Severe borderline personality disorder based on clinical assessment. 4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder 5. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal 6. Clinically significant suicidal ideation with plan 7. Any history of ECT (greater than 8 sessions) without a clinical meaningful response in the current episode. 8\. Recent (during the current depressive episode) or concurrent use of rapid-acting antidepressant agent (i.e., ketamine or a course of ECT) in the last 30 days 9. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma 10. Untreated or insufficiently treated endocrine disorder. 11. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) 12. Treatment with an investigational drug or other intervention within the study period 13. The patient experiences a relapse between baseline and screening, defined as a moderate depression (MADRS \>=20) and a 25% increase from screening to baseline 14. Require a benzodiazepine with a dose \> lorazepam 2 mg/day or equivalent or any anticonvulsant (with the exception of Gabapentin, pregabalin, and lamotrigine).